Cat. No. 3205
Alternative Name: Conotoxin Vc1.1
Biological ActivityNeuronal nicotinic receptor antagonist that displays selectivity for the α9α10 subtype (IC50 values are 19, 140, 980, 4200 and 7300 nM for α9α10, α6/α3β2β3, α6/α3β4, α3β4 and α3β2 subtypes respectively). Alleviates neuropathic pain in three rat models of human neuropathic pain and accelerates functional recovery of injured neurons.
Licensing InformationSold under license from Dr Bruce Livett
(Modifications: Cys-16 - C-terminal amide, Disulfide bridge between 2 - 8, 3 - 16)
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Sandall et al (2003) A novel α-conotoxin identified by gene sequencing is active in suppressing the vascular response to selective stimulation of sensory nerves in vivo. Biochemistry 42 6904. PMID: 12779345.
Vincler et al (2006) Molecular mechanism for analgesia involving specific antagonism of α9α10 nicotinic acetylcholine receptors. Proc.Nat.Acad.Sci.USA 103 17880.
Nevin et al (2007) Are α9α10 nicotinic acetylcholine receptors a pain target for α-conotoxins? Mol.Pharmacol 72 1406. PMID: 17804600.
Halai et al (2009) Scanning mutagenesis of α-conotoxin Vc1.1 reveals residues crucial for activity at the α9α10 nicotinic acetylcholine receptor J.Biol.Chem. 284 20275. PMID: 19447885.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: ACV 1, supplier, α9α10, alpha9alpha10, selective, a9, a10, antagonists, Acetylcholine, Nicotinic, Receptors, Non-Selective, Subtypes, nAChR, ACV1, ConotoxinVc11